• Lu-177 DOTA-TATE is a treatment method used in neuroendocrine tumors. (intheranostics.com)
  • The drug binds with DOTA-TATE to the surface of neuroendocrine tumors, and with Lutetium-177 a high dose of local radiotherapy is irradiated directly to the tumor. (intheranostics.com)
  • Studies show that lutetium therapy can improve life expectancy and quality and alleviate symptoms and complaints in people with neuroendocrine tumors. (intheranostics.com)
  • 177Lu DOTA-TATE was approved in the United States for the treatment of SSTR positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults, in January 2018. (wikipedia.org)
  • PNT2003, also known as lutetium-177 Octreotate (177Lu-DOTATATE), is a somatostatin receptor (SSTR) targeted radioligand therapy in development for the treatment of patients with SSTR-positive neuroendocrine tumors. (pointbiopharma.com)
  • Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. (radiopaedia.org)
  • Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). (wikipedia.org)
  • The European Commission approved lutetium (177Lu) oxodotreotide (trade name Lutathera) "for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults" in September 2017. (wikipedia.org)
  • The U.S. Food and Drug Administration (FDA) approved 177Lu dotatate based primarily on evidence from one clinical trial, NETTER-1 of 229 participants with somatostatin-receptor positive midgut GEP-NETs. (wikipedia.org)
  • The FDA considered additional data from a second study based on data from 1,214 participants with somatostatin receptor-positive tumors, including GEP-NETS, who received 177Lu dotatate at a single site in the Netherlands, Erasmus MC. (wikipedia.org)
  • 177)Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer. (nih.gov)
  • Gallium-68 DOTATATE​ ​ (or Ga-68 DOTATATE ) is a PET radiotracer that is a form of somatostatin-receptor (SSTR) functional imaging. (radiopaedia.org)
  • Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. (radiopaedia.org)
  • The goal of Lu-177 DOTA-TATE therapy is to slow or stop tumor growth and reduce some of the symptoms caused by the tumor. (intheranostics.com)
  • Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. (nih.gov)
  • Lu-177 DOTA-TATE treatment uses a drug consisting of DOTA-TATE, a man-made (synthetic) form of the natural somatostatin hormone, and the radioactive element Lutetium-177. (intheranostics.com)
  • Of these agents, Ga-68 DOTA-TATE PET / CT can visualize tumoral tissues with high sensitivity, and Lu-177 DOTA-TATE can perform specific and targeted treatment of tumoral tissues. (intheranostics.com)
  • Lu-177 DOTA-TATE treatment usually consists of four cycles administered 8 to 12 weeks apart. (intheranostics.com)
  • In this section, we aim to answer your questions about Lu-177 DOTA-TATE treatment and explain the benefits, risks and alternatives of treatment. (intheranostics.com)
  • Who is Lutetium-177 DODA-TATE Treatment Applied? (intheranostics.com)
  • Is Lutetium-177 DOTA-TATE Treatment Safe? (intheranostics.com)
  • Our NET patients receiving Lu-177 DOTA-TATE treatment experience minimal and less severe long-term side effects compared to other cancer treatments. (intheranostics.com)
  • The benefit of 177Lu dotatate was evaluated by measuring the length of time that tumors did not grow after treatment and compared it to the control group (progression free survival). (wikipedia.org)
  • The benefit of 177Lu dotatate was evaluated by measuring if and how much the tumor size changed during treatment (the overall response rate). (wikipedia.org)
  • Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). (wikipedia.org)
  • Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours. (cnets.ca)
  • Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. (ac.ir)
  • Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. (ac.ir)
  • Alternatives to 177Lu-DOTATE include yttrium-90 DOTATATE or DOTATOC. (wikipedia.org)
  • The longer range of the beta particles emitted by 90Y, which deliver the therapeutic effect, may make it more suitable for large tumors with 177Lu reserved for smaller volumes The U.S. Food and Drug Administration (FDA) considers 177Lu dotatate to be a first-in-class medication. (wikipedia.org)
  • The European Commission approved lutetium (177Lu) oxodotreotide (trade name Lutathera) "for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults" in September 2017. (wikipedia.org)
  • 177Lu DOTA-TATE was approved in the United States for the treatment of SSTR positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults, in January 2018. (wikipedia.org)
  • The U.S. Food and Drug Administration (FDA) approved 177Lu dotatate based primarily on evidence from one clinical trial, NETTER-1 of 229 participants with somatostatin-receptor positive midgut GEP-NETs. (wikipedia.org)
  • Participants were randomly assigned to receive either 177Lu dotatate with long-acting octreotide or long-acting octreotide, at a higher dose, alone. (wikipedia.org)
  • 177Lu dotatate was injected through the vein and long-acting octreotide was injected in the muscle. (wikipedia.org)
  • The benefit of 177Lu dotatate was evaluated by measuring the length of time that tumors did not grow after treatment and compared it to the control group (progression free survival). (wikipedia.org)
  • The FDA considered additional data from a second study based on data from 1,214 participants with somatostatin receptor-positive tumors, including GEP-NETS, who received 177Lu dotatate at a single site in the Netherlands, Erasmus MC. (wikipedia.org)
  • All participants received 177Lu dotatate with octreotide. (wikipedia.org)
  • The benefit of 177Lu dotatate was evaluated by measuring if and how much the tumor size changed during treatment (the overall response rate). (wikipedia.org)
  • Participants initially enrolled in the study received 177Lu dotatate as part of an expanded access program. (wikipedia.org)
  • The FDA granted the application for 177Lu dotatate priority review designation and orphan drug designation. (wikipedia.org)
  • The kidneys are particularly at risk as they help to remove 177Lu DOTA-TATE from the body. (wikipedia.org)
  • Lutathera® (lutetium (177Lu) oxodotreotide) was approved by Health Canada in January 2019, for the treatment of unresectable (not removable by surgery) or metastatic, well-differentiated, somatostatin receptor-positive (expressing the somatostatin receptor) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with progressive disease. (cnets.ca)
  • As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. (cnets.ca)
  • Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as "No Carrier Added" (NCA) 177Lu. (ac.ir)
  • We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu ("NCA-LuTATE") and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. (ac.ir)
  • Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. (ac.ir)
  • Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. (nih.gov)
  • A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 with potential antineoplastic activities. (hemonc.org)
  • Lutetium Lu 177-DOTA-TATE binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. (hemonc.org)
  • Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. (hemonc.org)
  • 8. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. (ac.ir)
  • Comparison and evaluation of nca and ca Lu-177-[DOTA (0), Tyr3] octreotate in (GEP-NETs) treated patients. (ac.ir)
  • Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. (nih.gov)